GO:0043039 tRNA charging: Aminoacyl-tRNA Synthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043039 tRNA charging (also called aminoacyl-tRNA biosynthesis) is the biological process that covalently attaches each amino acid to its cognate tRNA, forming aminoacyl-tRNA for ribosomal protein synthesis.
• The reaction is catalyzed by aminoacyl-tRNA synthetases (ARSs), which esterify the amino acid alpha-carboxyl group to the 3'-hydroxyl of the tRNA's 3'-terminal adenosine.
• tRNA charging is a major fidelity checkpoint: ARSs employ editing domains to hydrolyze mischarged tRNAs, preventing proteome-wide mistranslation.
• Selective tRNA charging and ARS expression are reprogrammed in cancer, and lysine-tRNA charging is a therapeutically targetable dependency in liver cancer.
• Mutations in nuclear-encoded mitochondrial ARSs cause inherited diseases including Charcot-Marie-Tooth neuropathy, leukoencephalopathy, and Perrault syndrome.
• Despite ubiquitous ARS expression, impaired tRNA charging produces cell-type-restricted phenotypes, making tissue-specific models essential.
Description
GO:0043039 tRNA charging, also known as aminoacyl-tRNA biosynthesis or tRNA aminoacylation, is the biological process that covalently links each amino acid to its corresponding tRNA molecule, producing the aminoacyl-tRNA substrates used by the ribosome for protein synthesis. The reaction is catalyzed by aminoacyl-tRNA synthetases (ARSs), a family of enzymes that activate an amino acid with ATP and then transfer it to the 3'-terminal adenosine of the tRNA via an ester bond. Because every codon must be decoded by a correctly charged tRNA, tRNA charging sits at the interface of translation, amino acid sensing, and cellular stress signaling. For researchers, tRNA charging is important because it is both a fundamental housekeeping process and a disease-relevant vulnerability. Selective tRNA charging has been observed in breast cancer, where specific ARSs and tRNA pools support tumor growth, and lysine-tRNA charging has been shown to be therapeutically targetable in liver cancer. In inherited disease, mutations in nuclear-encoded mitochondrial tRNA charging enzymes cause tissue-specific pathologies such as neuropathy and leukoencephalopathy. Moreover, although ARSs are ubiquitously expressed, impaired charging often produces restricted phenotypes, highlighting cell-type-specific sensitivities that require careful model selection. This article summarizes the QuickGO definition of GO:0043039, the molecular steps of tRNA charging, the key genes and enzymes involved, its regulation, its links to human disease, and the experimental and CRISPR-based methods used to study it. All statements are based on the verified literature cited by number.
tRNA charging At A Glance
| GO ID | GO:0043039 |
|---|---|
| GO term | tRNA charging |
| Ontology | biological_process |
| Synonym | amino acid activation; aminoacyl-tRNA biosynthesis; aminoacyl-tRNA biosynthetic process; aminoacyl tRNA synthesis; tRNA aminoacylation |
| Definition | The chemical reactions and pathways by which amino acids become bonded to their corresponding tRNAs, usually via ester bond formation between the tRNA 3'-terminal adenosine and the amino acid alpha-carboxyl group, catalyzed by cognate aminoacyl-tRNA ligases. |
| Major function | Production of aminoacyl-tRNA for ribosomal protein synthesis and maintenance of translational fidelity. |
| Key enzymes | Aminoacyl-tRNA synthetases (ARSs), including both cytosolic and mitochondrial enzymes. |
| Substrates | Amino acids, ATP, and tRNA molecules. |
| Products | Aminoacyl-tRNA, AMP, and pyrophosphate. |
| Disease relevance | Cancer dependencies, inherited mitochondrial ARS disorders, and cell-type-specific sensitivities. |
What Is GO:0043039?
According to the Gene Ontology, GO:0043039 tRNA charging is defined as the chemical reactions and pathways by which the various amino acids become bonded to their corresponding tRNAs. The most common route for synthesis of aminoacyl-tRNA is the formation of an ester bond between the 3'-hydroxyl group of the most 3' adenosine of the tRNA and the alpha carboxylic acid group of an amino acid, usually catalyzed by the cognate aminoacyl-tRNA ligase. A given aminoacyl-tRNA ligase aminoacylates all species of an isoaccepting group of tRNA molecules.
Why Is tRNA charging Important in Cell Biology?
tRNA charging is essential because it provides the aminoacyl-tRNA substrates that decode mRNA codons during translation, and its accuracy directly determines proteome fidelity. Beyond housekeeping, tRNA charging is a regulatory node that integrates amino acid availability, cellular stress, and growth signaling, and it is increasingly recognized as a therapeutic target in cancer and as a cause of inherited disease when mutated.
• Provides aminoacyl-tRNA for every codon in the genetic code, making it indispensable for protein synthesis.
• Maintains translational fidelity through ARS editing and quality control mechanisms that hydrolyze mischarged tRNAs.
• Supports selective tRNA charging programs in breast cancer that favor tumor growth.
• Represents a therapeutically targetable dependency in liver cancer through lysine-tRNA charging.
• Links to inherited diseases caused by mutations in nuclear-encoded mitochondrial tRNA charging enzymes.
• Shows cell-type-specific sensitivities despite ubiquitous ARS expression, informing tissue-specific disease models.
• Is a target of natural product inhibitors such as tetracyclines, which affect aminoacyl-tRNA interactions.
• Is being explored for drug discovery through chemical inhibition of tRNA aminoacylation.
• Connects amino acid metabolism and stress signaling to translation control.
• Provides biomarkers and mechanistic hypotheses for ARS-related neuropathies and leukoencephalopathies.
What Happens During tRNA charging?
Amino acid activation by aminoacyl-tRNA synthetases
In simple terms: The enzyme first uses ATP to activate the amino acid, making it ready to attach to tRNA.
In the first step of tRNA charging, the cognate aminoacyl-tRNA synthetase binds its amino acid and ATP, forming an aminoacyl-adenylate intermediate with release of pyrophosphate. This activation step is conserved across the ARS family and ensures that the correct amino acid is selected before transfer to tRNA.
Ester bond formation with the tRNA 3'-end
In simple terms: The activated amino acid is then glued onto the tail of the tRNA molecule.
The activated amino acid is transferred to the 3'-hydroxyl group of the most 3' adenosine of the tRNA, forming an ester bond and yielding aminoacyl-tRNA. A given aminoacyl-tRNA ligase aminoacylates all species of an isoaccepting group of tRNA molecules, ensuring that synonymous tRNAs are charged with the same amino acid.
Editing and quality control
In simple terms: If the wrong amino acid is attached, the enzyme can proofread and remove it.
Many ARSs possess editing domains that hydrolyze mischarged aminoacyl-tRNAs, preventing mistranslation and proteome damage. Quality control in tRNA charging is therefore a critical fidelity mechanism that complements codon-anticodon pairing at the ribosome.
Delivery to the ribosome and translation
In simple terms: The charged tRNA is delivered to the ribosome so its amino acid can be added to a growing protein.
Once formed, aminoacyl-tRNA is bound by elongation factor complexes and delivered to the ribosomal A site, where codon-anticodon pairing directs incorporation of the amino acid into the nascent polypeptide. This step couples tRNA charging directly to the rate and accuracy of protein synthesis.
Mitochondrial tRNA charging
In simple terms: Mitochondria have their own set of charging enzymes for their own tRNAs.
Nuclear-encoded mitochondrial aminoacyl-tRNA synthetases charge mitochondrial tRNAs, supporting oxidative phosphorylation complex assembly and mitochondrial translation. Mutations in these enzymes cause inherited diseases with tissue-specific phenotypes, reflecting the high energy demand of neurons and other affected tissues.
Key Genes Involved in GO:0043039 tRNA charging
The genes below encode aminoacyl-tRNA synthetases and related factors that catalyze or regulate tRNA charging; they are commonly studied in cancer, inherited disease, and translation research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AARS1 | Cytosolic alanyl-tRNA synthetase that charges tRNA-Ala | Editing defects and mistranslation studies |
| AARS2 | Mitochondrial alanyl-tRNA synthetase | Mitochondrial disease and cardiomyopathy models |
| KARS1 | Lysyl-tRNA synthetase that charges tRNA-Lys | Lysine-tRNA charging is targetable in liver cancer |
| LARS1 | Leucyl-tRNA synthetase | mTOR signaling and amino acid sensing |
| MARS1 | Methionyl-tRNA synthetase | Charcot-Marie-Tooth neuropathy and lung disease models |
| GARS1 | Glycyl-tRNA synthetase | Charcot-Marie-Tooth neuropathy type 2D |
| YARS1 | Tyrosyl-tRNA synthetase | Dominant neuropathy and angiogenesis-related research |
| DARS1 | Aspartyl-tRNA synthetase | Hypomyelinating leukoencephalopathy models |
| DARS2 | Mitochondrial aspartyl-tRNA synthetase | Leukoencephalopathy with brainstem and spinal cord involvement |
| EARS2 | Mitochondrial glutamyl-tRNA synthetase | Leukoencephalopathy and mitochondrial translation studies |
| RARS2 | Mitochondrial arginyl-tRNA synthetase | Pontocerebellar hypoplasia models |
| HARS1 | Histidyl-tRNA synthetase | Peripheral neuropathy and immune signaling research |
| IARS1 | Isoleucyl-tRNA synthetase | Growth restriction and editing studies |
| VARS1 | Valyl-tRNA synthetase | Neurodevelopmental and microcephaly models |
| WARS1 | Tryptophanyl-tRNA synthetase | Angiogenesis and interferon-related research |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase | Multisynthetase complex and immune regulation |
| MARS2 | Mitochondrial methionyl-tRNA synthetase | Mitochondrial disease and deafness models |
How Is tRNA charging Regulated?
tRNA charging is regulated at multiple levels. ARS expression and activity are coupled to amino acid availability and growth signaling, and ARSs participate in pathways such as mTOR signaling that sense nutrient status. Quality control mechanisms, including ARS editing domains, regulate the fidelity of charging by hydrolyzing mischarged tRNAs. In cancer, selective tRNA charging programs can be reprogrammed to support tumor growth, indicating context-dependent regulation. Additionally, cell-type-specific sensitivities to impaired tRNA charging suggest that tissue-specific factors modulate the consequences of ARS dysfunction.
tRNA charging and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KARS1 | Liver cancer dependency via lysine-tRNA charging | Knockout and point-mutation models in liver cancer cell lines |
| MARS1 | Charcot-Marie-Tooth neuropathy | Knock-in of patient mutations in neuronal cells |
| DARS2 | Leukoencephalopathy with brainstem and spinal cord involvement | Mitochondrial ARS knockout in glial models |
| AARS1 | Mistranslation and editing defects | Editing-domain point mutants in HEK293 or cancer lines |
| LARS1 | mTOR signaling and amino acid sensing | Knockout and overexpression in nutrient-sensing studies |
tRNA charging in cancer
Selective tRNA charging has been observed in breast cancer, where specific charging programs support tumor growth and may represent therapeutic vulnerabilities. In liver cancer, lysine-tRNA charging is therapeutically targetable, and inhibition of this process impairs tumor growth. These findings position tRNA charging as a cancer dependency that can be explored with ARS-targeted models.
Inherited mitochondrial tRNA charging disorders
Mutations in nuclear-encoded mitochondrial tRNA charging enzymes cause human inherited diseases, including Charcot-Marie-Tooth neuropathy, leukoencephalopathy, and Perrault syndrome. These disorders often show tissue-specific phenotypes despite ubiquitous enzyme expression, reflecting the metabolic demands of affected tissues.
Cell-type-specific sensitivities and ribosomopathies
Ubiquitously expressed proteins such as ARSs can produce restricted phenotypes when impaired, suggesting that cell-type-specific sensitivities shape disease presentation. This concept is relevant to ribosomopathy-like conditions and to interpreting genotype-phenotype relationships in tRNA charging defects.
Pharmacological targeting of tRNA charging
Drugging tRNA aminoacylation is an active area of research, with efforts to develop inhibitors of ARSs for cancer and infectious disease. Natural products such as tetracyclines affect aminoacyl-tRNA interactions, illustrating the historical and ongoing interest in targeting this process.
From tRNA charging-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is an ARS required for cancer cell growth? | CRISPR knockout in cancer cell lines followed by viability assays |
| Does a patient mutation impair tRNA charging? | Point-mutation knock-in of the patient allele |
| Can a tagged ARS be used to study localization? | Knock-in of an epitope tag at the endogenous locus |
| Does ARS overexpression drive transformation? | Overexpression cell models in primary or immortalized cells |
| Which tRNAs are charged under stress? | tRNA charging assays combined with RNA-seq and proteomics |
| Does loss of an ARS cause tissue-specific phenotypes? | Tissue-specific knockout or conditional models |
How to Study the tRNA charging Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acid-urea PAGE | Ratio of charged to uncharged tRNA | ARS mutation and inhibitor studies |
| tRNA microarray | Global tRNA charging levels | Cancer and stress response profiling |
| Ribo-seq | Translation efficiency and ribosome pausing | Codon-specific effects of charging defects |
| Mass spectrometry proteomics | Mistranslation and protein expression changes | Editing-domain and fidelity studies |
| CRISPR knockout screens | Gene dependencies and modifiers | Cancer and tissue-specific sensitivity |
| RNA-seq | Transcriptional responses to charging stress | Pathway and stress signaling analysis |
| Immunofluorescence imaging | Subcellular localization of ARSs | Mitochondrial and cytosolic charging studies |
tRNA charging and aminoacylation assays
Direct measurement of aminoacyl-tRNA levels using acid-urea gels, tRNA microarrays, or liquid chromatography-mass spectrometry can quantify charging status. These assays are used to test whether ARS mutations or inhibitors alter the ratio of charged to uncharged tRNA.
Ribosome profiling and translation profiling
Ribo-seq and polysome profiling measure the impact of impaired tRNA charging on translation efficiency and codon-specific ribosome pausing. These methods link charging defects to changes in protein synthesis and stress responses.
Proteomics and mistranslation detection
Mass spectrometry-based proteomics can detect mistranslation events caused by ARS editing defects, providing a readout of translational fidelity. This approach is valuable for studying quality control in tRNA charging.
Genetic and CRISPR screens
CRISPR knockout and library screens identify ARS dependencies and modifiers of tRNA charging phenotypes across cell types. Such screens help uncover selective vulnerabilities in cancer and tissue-specific sensitivities.
How CRISPR Can Be Used to Study GO:0043039 tRNA charging
Knockout
CRISPR knockout of ARS genes is used to test whether tRNA charging is required for cell growth, survival, or stress responses. Knockout models help identify selective dependencies, such as lysine-tRNA charging in liver cancer.
Point Mutation
Point-mutation knock-in of patient-derived ARS variants allows researchers to study loss-of-function or editing defects in an endogenous context. These models are particularly useful for inherited mitochondrial tRNA charging disorders.
Knock-in
Knock-in of epitope tags or fluorescent reporters at ARS loci enables localization and interaction studies without overexpression artifacts. Tagged knock-in models support imaging and proteomic analyses of tRNA charging machinery.
Overexpression
Overexpression of ARSs or tRNA molecules is used to model selective tRNA charging programs observed in cancer and to test whether increased charging promotes transformation. Overexpression models complement loss-of-function studies by revealing gain-of-function phenotypes.
How EDITGENE Supports tRNA charging Research
Researchers studying tRNA charging-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer growth, mitochondrial dysfunction, or translational fidelity. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point-mutation, knock-in, and overexpression studies of ARS genes and related factors, supported by library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for tRNA charging research.
Frequently Asked Questions About tRNA charging
What is tRNA charging (GO:0043039)?
tRNA charging is the biological process that attaches each amino acid to its corresponding tRNA, forming aminoacyl-tRNA for protein synthesis, catalyzed by aminoacyl-tRNA synthetases.
What genes are involved in tRNA charging?
Genes encoding aminoacyl-tRNA synthetases such as AARS1, KARS1, LARS1, MARS1, GARS1, YARS1, DARS1, DARS2, EARS2, RARS2, HARS1, IARS1, VARS1, WARS1, EPRS1, and MARS2 are involved in tRNA charging.
Why is tRNA charging important for translation?
It provides the aminoacyl-tRNA substrates that decode mRNA codons, and its fidelity mechanisms prevent mistranslation.
How is tRNA charging regulated?
It is regulated by amino acid availability, growth signaling such as mTOR, ARS editing quality control, and context-dependent programs in cancer.
What diseases are linked to tRNA charging defects?
Mutations in mitochondrial ARS genes cause inherited diseases including Charcot-Marie-Tooth neuropathy, leukoencephalopathy, and Perrault syndrome, and charging is also linked to cancer.
Can tRNA charging be targeted therapeutically?
Yes, drugging tRNA aminoacylation is an active area, and lysine-tRNA charging is targetable in liver cancer.
What methods are used to study tRNA charging?
Acid-urea PAGE, tRNA microarrays, Ribo-seq, proteomics, RNA-seq, imaging, and CRISPR screens are commonly used.
What is the role of aminoacyl-tRNA synthetases in tRNA charging?
They activate amino acids with ATP and transfer them to the tRNA 3'-end, and many also edit mischarged tRNAs.
Are mitochondrial tRNA charging enzymes different from cytosolic ones?
Yes, nuclear-encoded mitochondrial ARSs charge mitochondrial tRNAs and are associated with distinct inherited diseases.
How can CRISPR help study tRNA charging?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of ARS genes in disease and translation research.
Conclusion
GO:0043039 tRNA charging is a central biological process that supplies aminoacyl-tRNA for protein synthesis and maintains translational fidelity through ARS editing and quality control. Its dysfunction is linked to cancer dependencies, inherited mitochondrial diseases, and cell-type-specific phenotypes, making it a rich area for mechanistic and therapeutic research. CRISPR-based cell models and functional genomics approaches provide powerful tools to dissect the causal roles of tRNA charging genes in health and disease.
References
- 1. Vincent CT et al.. 2022. Selective tRNA charging in breast cancer.. Nat Cell Biol 24(3):287-289 PMID: 35288657
- 2. Del Greco C et al.. 2022. The Role of Nuclear-Encoded Mitochondrial tRNA Charging Enzymes in Human Inherited Disease.. Genes (Basel) 13(12) PMID: 36553587
- 3. Jakubowski H. 2012. Quality control in tRNA charging.. Wiley Interdiscip Rev RNA 3(3):295-310 PMID: 22095844
- 4. Ho JM et al.. 2018. Drugging tRNA aminoacylation.. RNA Biol 15(4-5):667-677 PMID: 29345185
- 5. Kuo ME et al.. 2020. Ubiquitously Expressed Proteins and Restricted Phenotypes: Exploring Cell-Specific Sensitivities to Impaired tRNA Charging.. Trends Genet 36(2):105-117 PMID: 31839378
- 6. Zhang R et al.. 2021. The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer.. Liver Int 41(1):206-219 PMID: 33084231
- 7. Tijaro-Bulla S et al.. 2023. Physiological and engineered tRNA aminoacylation.. Wiley Interdiscip Rev RNA 14(5):e1789 PMID: 37042417
- 8. Laskin AI et al.. 1971. Tetracyclines.. Antibiot Chemother (1971) 17:1-28 PMID: 4950998
